Telix Publishes ProstACT SELECT Study on TLX591-Tx
Melbourne, Australia & Indianapolis, Indiana, USA | July 22, 2026 Telix Pharmaceuticals announced the peer-reviewed publication of results from...
mCRPC
Advertisement
ORIC Launches Phase 3 Himalayas-1 Trial
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 14, 2026 ORIC Pharmaceuticals announced the initiation of the global Himalayas-1...
Telix Secures FDA Alignment to Advance ProstACT Phase 3 Trial
Melbourne, Australia, and Indianapolis, Indiana, United States, July 2, 2026 Telix announced a significant regulatory milestone after a successful...
Telix Presents Encouraging Phase 3 Results for TLX591-Tx at ASCO 2026
MELBOURNE, Australia & INDIANAPOLIS, U.S., June 2, 2026 Telix Pharmaceuticals announced positive Part 1 data from its global Phase...
Convergent’s CONV01-α Shows Promising Activity in Post-Lu-PSMA Prostate Cancer Phase 2 Study
CAMBRIDGE, Mass., June 2, 2026 Convergent Therapeutics announced positive interim Phase 2 data from its CONVERGE-01 study evaluating CONV01-α...
Advertisements
Foundation Medicine Gains FDA Approval for TALZENNA CDx
BOSTON, June 1, 2026 Foundation Medicine announced that the U.S. Food and Drug Administration (FDA) has approved both FoundationOne®...
Haisco and Lilly Forge $3B Deal to Advance New Medicines
SILICON VALLEY, Calif. & BEIJING, June 1, 2026 Haisco Pharmaceutical Group Co., Ltd. has announced a landmark licensing and...
Curium Invests €32M to Expand Prostate Cancer RLT Production
PARIS, France, June 1, 2026 Curium, a global leader in radiopharmaceuticals and nuclear medicine, has announced a strategic investment...
Aktis Oncology Starts Phase 1b Trial for AKY-2519
BOSTON, May 04, 2026 Aktis Oncology has announced the initiation of a Phase 1b clinical trial evaluating AKY-2519, a...
Telix Advances TLX597-Tx Phase 2 Prostate Cancer Program
MELBOURNE, Australia & INDIANAPOLIS, IN, April 30, 2026 Telix Pharmaceuticals has announced encouraging dosimetry results from its Phase 2...
Advertisement
